Eskayef Pharmaceuticals Limited is one of the leading pharmaceutical companies in Bangladesh. The company was incorporated in 1979 as a subsidiary of SmithKline & French, USA, and was acquired by the leading conglomerate of Bangladesh, Transcom Ltd., in 1990. This was the first acquisition of a renowned multinational company by a Bangladeshi entity. Eskayef is engaged in the manufacturing and mark
eting of pharmaceutical finished products and animal health products for local and international markets. In 2022, Eskayef became the first Bangladeshi pharmaceutical company to export injectable products to the USA. The company received US FDA approval for its injectable and solid manufacturing facilities. Eskayef has also received global accreditations from the UK MHRA, EU GMP, Brazil ANVISA, Australia TGA and South Africa SAHPRA. As a technical alliance partner, Eskayef has been manufacturing high-tech insulin vials for Novo Nordisk in Bangladesh since 2012 and will soon begin manufacturing modern Penfill insulin for Novo Nordisk. The company has also launched a complete portfolio of oncology products from its state-of-the-art oncology facility, which is the only one in Bangladesh to receive EU GMP and Brazil ANVISA approvals. During the COVID-19 pandemic, Eskayef launched the world's first generic versions of Remdesivir (Remivir), Molnupiravir (Monuvir), and Nirmatrelvir+Ritonavir (Paxovir) immediately after the international parent brand's launch, which greatly helped the people of Bangladesh and 49 countries worldwide in the fight against COVID-19. Eskayef has five manufacturing plants and a dedicated R&D center, where talented individuals focus on technology-driven molecules to address unmet patient needs. The company is continuously expanding its global footprint and currently exports its medicines to 70 countries across six continents, including Asia, Africa, Europe, Australia, South America, and North America.
